Hyperlipoproteinemia (a) research hub

An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

This study looks at the long-term safety of a new medicine, pelacarsen, for people with high lipoprotein(a) and heart disease. It's for those who have already been in a previous study and will last about 5 years to see how they get on with the treatment.